Annual report pursuant to Section 13 and 15(d)

Strategic Alliances (Details)

v3.6.0.2
Strategic Alliances (Details) - USD ($)
1 Months Ended 3 Months Ended 8 Months Ended 12 Months Ended
May 31, 2016
Nov. 30, 2015
Jan. 31, 2015
Dec. 31, 2010
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Jul. 31, 2015
Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue           $ 162,400,000 $ 162,400,000 $ 232,900,000      
Grant repayment         $ 25,900,000   0 25,889,000 $ 0    
Intangible assets, net           763,976,000 763,976,000 638,152,000      
Vifor Fresenius Medical Care Pharma Ltd                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone revenue recognized           0          
Vifor Fresenius Medical Care Pharma Ltd | Development and License Agreement                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Proceeds from license fees received $ 50,000,000           50,000,000.0        
Royalty revenue, obligation period 10 years                    
Vifor Fresenius Medical Care Pharma Ltd | Exclusive Option                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments, maximum $ 555,000,000                    
Vifor Fresenius Medical Care Pharma Ltd | Regulatory Milestones                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments, maximum 37,000,000                    
Vifor Fresenius Medical Care Pharma Ltd | Launch and Sales-based Milestones                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments, maximum $ 195,000,000                    
TESARO                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments, maximum       $ 30,000,000.0              
Upfront payment under license agreements       6,000,000              
Milestone revenue to date           20,000,000 20,000,000        
Additional milestone payment       $ 85,000,000.0              
Maximum period to receive royalties       12 years              
TESARO | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone revenue recognized             0 $ 15,000,000 $ 5,000,000    
Merck | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Amount payable each year   $ 5,000,000                  
Yearly payment period   4 years                  
Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments, maximum     $ 275,000,000                
Non-refundable upfront payment     295,000,000       295,000,000        
Additional milestone payment to be received     275,000,000                
Revenue from sale of intellectual property             70,600,000        
Deferred revenue           158,900,000 158,900,000        
Research and development expenses related to hGH-CTP             45,900,000        
RXi Pharmaceuticals Corporation                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments                     $ 50,000,000
Accrued Expenses | Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue           70,600,000 70,600,000        
Other Long-term Liabilities | Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue           $ 88,300,000 $ 88,300,000        
Minimum                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Intangible assets, estimated useful lives             3 years        
Minimum | Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payment ranges     20,000,000                
Maximum                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Intangible assets, estimated useful lives             20 years        
Maximum | Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payment ranges     $ 90,000,000                
Pharmsynthez                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Ownership percentage           17.00% 17.00%        
Notes | Pharmsynthez Note Receivable | Pharmsynthez                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Debt face amount                   $ 3,000,000.0  
Licenses | Merck | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Intangible assets, net   $ 23,000,000       $ 14,000,000 $ 14,000,000        
Intangible assets, estimated useful lives   13 years                  
Licenses | Accrued Expenses | Merck | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Intangible assets, net           4,900,000 4,900,000        
Licenses | Other Long-term Liabilities | Merck | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Intangible assets, net           $ 9,100,000 $ 9,100,000